Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06468670 | Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 21, 2024 | clinicaltrials |
| NCT06468969 | Enhanced vs. Routine Follow-Up After Total Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial | not yet recruiting | N/A | 158 | Fudan UniversityOTHER | 0 | Jun 21, 2024 | clinicaltrials |
| NCT06463548 | Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma | not yet recruiting | N/A | 30 | Yunpeng LiuOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06464601 | A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer | not yet recruiting | — | 70 | Wuhan UniversityOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06463327 | ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML(ACHIEVE2) | not yet recruiting | Phase 1 | 69 | TC BiopharmINDUSTRY | 0 | Jun 17, 2024 | clinicaltrials |
| NCT06448611 | Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radiotherapy) in a Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma(MERCCALIBI) | not yet recruiting | — | 25 | University Hospital, MontpellierOTHER | 0 | Jun 13, 2024 | clinicaltrials |
| NCT06456138 | Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC | not yet recruiting | Phase 1 / Phase 2 | 60 | Shanghai Chest HospitalOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT06453785 | Comparing pOrtable MRI and TRUS-Fusion Prostate Biopsy to Assess aCcuracy of Prostate Cancer Detection(IP10-COMPACT) | not yet recruiting | N/A | 85 | Imperial College LondonOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT06453889 | Efficacy and Safety of Multimode Thermal Therapy in the Treatment of Early Peripheral Lung Cancer | not yet recruiting | N/A | 10 | Shanghai Chest HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT06454435 | Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer | not yet recruiting | Phase 2 | 158 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT06454890 | Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 1 / Phase 2 | 50 | Henan Cancer HospitalOTHER_GOV | 0 | Jun 12, 2024 | clinicaltrials |
| NCT06326853 | Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models | not yet recruiting | — | 200 | IRCCS San RaffaeleOTHER | 0 | Jun 11, 2024 | clinicaltrials |
| NCT06452433 | Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer. | not yet recruiting | Phase 2 | 91 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 11, 2024 | clinicaltrials |
| NCT06449846 | Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma | not yet recruiting | — | 152 | Zhujiang HospitalOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT06450574 | Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Ttransanal Endoscopic Microsurgery in T1 N0, M0 Rectal Cancer (TAUTEM-T1 Study)(TAUTEM-T1) | not yet recruiting | Phase 3 | 106 | Corporacion Parc TauliOTHER | 0 | Jun 10, 2024 | clinicaltrials |
| NCT06450821 | PROSpECT-PRIOR-2-CHEMO: PRIOR Dental Intervention Before Chemo to Reduce Chemotherapy Complications | not yet recruiting | N/A | 60 | University of LeedsOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT06446388 | Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors | not yet recruiting | Phase 2 | 360 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 6, 2024 | clinicaltrials |
| NCT06443671 | Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer(PKUCH-R09) | not yet recruiting | Phase 2 / Phase 3 | 132 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT06275997 | GAIN Project: Gastric Cancer and Artificial Intelligence(GAIN) | not yet recruiting | N/A | 6,600 | Istituto Clinico HumanitasOTHER | 0 | Jun 4, 2024 | clinicaltrials |
| NCT06297772 | Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR | not yet recruiting | Phase 3 | 220 | Ruijin HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06441045 | Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI | not yet recruiting | Phase 2 | 112 | Fujian Cancer HospitalOTHER_GOV | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06441084 | A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation | not yet recruiting | Phase 1 | 15 | Nuwacell Biotechnologies Co., Ltd.INDUSTRY | 0 | Jun 4, 2024 | clinicaltrials |
| NCT06441097 | Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | not yet recruiting | Phase 2 | 152 | Ruijin HospitalOTHER | 0 | Jun 4, 2024 | clinicaltrials |
| NCT06441344 | Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell(SCLC) | not yet recruiting | Phase 3 | 136 | Taizhou HospitalOTHER | 0 | Jun 4, 2024 | clinicaltrials |
| NCT06442605 | Clinical Research on the Application of Single-channel Uterine Fibroid Morcellation System in Laparoscopic Myomectomy | not yet recruiting | N/A | 22 | First People's Hospital of HangzhouOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06438939 | NBI for Early Diagnosis of OPMD/OSCC(NBI_Oral) | not yet recruiting | N/A | 480 | Cardarelli HospitalOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT06439550 | Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC | not yet recruiting | Phase 2 | 42 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Jun 3, 2024 | clinicaltrials |
| NCT06422949 | Efficacy and Safety of HILOTERM® Device for the Prevention of Peripheral Neuropathy | not yet recruiting | N/A | 120 | European Institute of OncologyOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06434740 | A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC | not yet recruiting | Phase 2 | 37 | Sir Run Run Shaw HospitalOTHER | 0 | May 30, 2024 | clinicaltrials |
| NCT06435689 | Study and Modulation of Immune Responses in Primary and Metastatic Colon Cancers(I-COMET) | not yet recruiting | — | 500 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT06435702 | Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study | not yet recruiting | — | 108 | Peking University Third HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT06436144 | Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC | not yet recruiting | Phase 2 | 93 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | May 30, 2024 | clinicaltrials |
| NCT06432075 | Neoantigen Reactive T Cells c for Chinese Patients With Advanced Gastric Cancer | not yet recruiting | Early Phase 1 | 20 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | May 29, 2024 | clinicaltrials |
| NCT06430411 | Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study(OLIGOMET) | not yet recruiting | — | 500 | Medical University of ViennaOTHER | 0 | May 28, 2024 | clinicaltrials |
| NCT06426056 | Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial. | not yet recruiting | Phase 2 | 64 | Peking University Third HospitalOTHER | 0 | May 23, 2024 | clinicaltrials |
| NCT06426654 | Sintilimab Combined With LDRT for Neoadjuvant Treatment of Locally Advanced dMMR/MSI-H Gastric Cancer | not yet recruiting | Phase 1 / Phase 2 | 45 | West China HospitalOTHER | 0 | May 23, 2024 | clinicaltrials |
| NCT06426797 | Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 25 | Peking University People's HospitalOTHER | 0 | May 23, 2024 | clinicaltrials |
| NCT06427213 | This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma | not yet recruiting | Phase 2 | 41 | Henan Cancer HospitalOTHER_GOV | 0 | May 23, 2024 | clinicaltrials |
| NCT06423937 | Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 129 | Fudan UniversityOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT06424054 | Mitigating Toxicity by Electronic Health Portal-mediated Interactive Monitoring of Patient-reported Side Effects(eChemoCoach) | not yet recruiting | N/A | 746 | Noordwest ZiekenhuisgroepOTHER | 0 | May 21, 2024 | clinicaltrials |
| NCT06421220 | Evaluation of the Efficacy and Safety of Indocyanine Green Tracing in 3D Fluorescent Laparoscopic Lymph Node Dissection for Gastric Cancer | not yet recruiting | N/A | 484 | Qilu Hospital of Shandong UniversityOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT06421974 | Effectiveness of Robotic Surgery for Right Colon Cancer | not yet recruiting | N/A | 610 | Sir Run Run Shaw HospitalOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT06418516 | Early Detection of Esophageal Squamous Cancer With the Capsule Sponge Device(ANGELA) | not yet recruiting | N/A | 340 | Centre of Postgraduate Medical EducationOTHER | 0 | May 17, 2024 | clinicaltrials |
| NCT06414915 | Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation | not yet recruiting | Phase 2 | 29 | National Cancer Center, ChinaOTHER | 0 | May 16, 2024 | clinicaltrials |
| NCT06415500 | A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant Ascites | not yet recruiting | Phase 1 | 9 | Anhui Provincial HospitalOTHER_GOV | 1 | May 16, 2024 | clinicaltrials |
| NCT06416267 | Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)(MBL RiskConseq) | not yet recruiting | — | 1,500 | University of HaifaOTHER | 0 | May 16, 2024 | clinicaltrials |
| NCT05982275 | Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant(CARTemis-1) | not yet recruiting | Phase 1 / Phase 2 | 25 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06276738 | The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease | not yet recruiting | — | 1,000 | Adenocyte, LLCINDUSTRY | 0 | May 14, 2024 | clinicaltrials |
| NCT06067620 | Robotic Right Hemicolectomy Versus Laparoscopic Right Hemicolectomy(PRORHEM) | not yet recruiting | N/A | 70 | Jeremy MeyerOTHER | 0 | May 10, 2024 | clinicaltrials |
| NCT06409429 | Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer | not yet recruiting | Phase 2 / Phase 3 | 146 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 10, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Jun 21, 2024source: clinicaltrials